Wegovy Starting Doses Restrictions Will Continue Through The Year
Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.

Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.